Skip to content
thestock.space

As of 6 Nov 2026, Bacil Pharma trades at 89.7× trailing earnings, above the industry P/E of 28.7×, and the shares are 72% below their 52-week high. Its ROCE of 4.0% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.22× equity. It is a small-cap company with a market cap of ₹24 Cr, ranked 140th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 43% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹18.29
Day high
₹18.29
Day low
₹17.02
Prev. close
₹17.91
Volume
13.7K

Health check

1 good · 4 to check
  • ReturnsBehind

    −42.6% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 89.7 vs industry 28.7.

  • Growthn/a

    Not enough yearly results to measure.

  • ProfitabilityWeak

    ROCE 4.0% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.22× equity.

  • Red flags4 to check

    Return on equity is low at 3.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹24 Cr, #140 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Market cap
₹24 Cr
Small cap
P/E
89.7
Industry 28.7
Price to book
0.81
Peers 4.99
Dividend yield
0.00%
ROE
3.0%
Peers 14.7%
ROCE
4.0%
Peers 17.9%
Debt to equity
0.22
Debt ₹5.52 Cr
EPS (TTM)
₹0.19
OPM (TTM)
0.0%
Net margin 0.0%
Sales growth
n/a
Year-ago quarter not reported
Profit growth
−623.2%
Latest quarter vs a year ago
Price to sales
n/a

Strengths and risks

Risks to check

  • Return on equity is low at 3.0%.
  • Quarterly profit down 623.2% on a year ago.
  • P/E of 89.7 against an industry P/E of 28.7.
  • 72% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Bacil Pharma

Bacil Pharma Limited develops, manufactures, and distributes pharmaceuticals products in India. The company offers pharmaceutical formulations, including tablets, capsules, injectables, ointments, and specialty products. Bacil Pharma Limited was incorporated in 1987 and is based in Mumbai, India.

Headquarters
Mumbai
Employees
2
Sector
Healthcare
ISIN
INE711D01018
Website
bacilpharma.co.in

Price range

52 weeks

₹10.65₹61.80

Today

₹17.02₹18.29
Avg volume (3M)
65.2K
1-year return
minus 42.6%
From 52-week high
minus 72.4%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
BACPHARBacil Pharma17.04minus 4.86%2489.70.814.0%3.0%0.0%––0.00%minus 42.6%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
Operating profit (EBITDA)Select a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
−0−0−0.1−0−0.1
0.10.10.10.10.1
––––0.1
0000.1−0
25.0%–−1497.9%124.2%−141.5%
000.6−0−0.1
0.010.030.440.22-0.06

Profit & loss

Yearly, ₹ crore
ROE
3.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−0.2−0.2−0.2−0.2
000.11.2
000–
000–
00.10.5−0.1
−0.1−0.10.41
0.0%0.1%0.8%−57.1%
−0.1−0.10.41.6
-0.17-0.100.641.11

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6.56.51414
−5.4−5.311.510.8
00.10.2–
0002.6
1.11.325.627.4
00––
0.20.621.424.2
0.202.90.6
0.70.71.42.6
1.11.325.627.4

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−0.1−00.40.7
−0.10.10.3−2.4
0.1−0.12.1−0.6
−0.202.8−2.3
−0.1−00.40.7

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you